Article Details
Retrieved on: 2022-12-14 18:01:49
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Immix Biopharma Inc (NASDAQ: IMMX) announced it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 (formerly HBI0101).
Article found on: www.benzinga.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here